Dataset.
2022
Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
CORA.Repositori de Dades de Recerca
doi:10.34810/data93
CORA.Repositori de Dades de Recerca
- Augusto J. Nhabomba
- Carlota Dobaño
- Chenjerai Jairoce
- David Cavanagh
- Deepak Gaur
- Evelina Angov
- Gemma Moncunill
- Inocencia Cuamba
- Itziar Ubillos
- James G. Beeson
- Joseph J. Campo
- Lina Sánchez
- Marta Vidal
- Nana Aba Williams
- Núria Diez-Padrisa
- Pedro Carlos Paulino Aide
- Ross L. Coppel
- Ruth Aguilar
- Sheetij Dutta
The RTS,S/AS01E vaccine has shown consistent but partial vaccine efficacy in a pediatric phase 3 26 clinical trial using a 3-dose immunization schedule. A fourth dose 18 months after the primary 27 vaccination was shown to restore the waning efficacy. However, only total IgG against the 28 immunodominant malaria vaccine epitope has been analyzed following the booster. To better 29 characterize the magnitude, nature and longevity of the immune response to the booster, we 30 measured levels of total IgM, IgG and IgG1-4 subclasses against three constructs of the 31 circumsporozoite protein (CSP) and the hepatitis B surface antigen (HBsAg, also present in RTS,S) 32 by quantitative suspension array technology in 50 subjects in the phase 3 trial in Manhiça, 33 Mozambique. To explore the impact of vaccination on naturally acquired immune responses, we 34 measured antibodies to P. falciparum antigens not included in RTS,S. We found increased IgG, 35 IgG1, IgG3 and IgG4, but not IgG2 nor IgM, levels against vaccine antigens one month after the 4th 36 dose. Overall, antibody responses to the booster dose were lower than the initial peak 37 response to primary immunization and children had higher IgG and IgG1 levels than infants. 38 Higher anti-Rh5 IgG and IgG1-4 levels were detected after the booster dose, suggesting that RTS,S 39 partial protection could increase some blood stage antibody responses. Our work shows that the 40 response to the RTS,S/AS01E booster dose is different from the primary vaccine immune 41 response and highlights the dynamic changes in subclass antibody patterns upon the vaccine 42 booster and with acquisition of adaptive immunity to malaria.
No hay resultados en la búsqueda
×
1 Documentos relacionados
1 Documentos relacionados
Dipòsit Digital de la UB
oai:diposit.ub.edu:2445/182854
Artículo científico (article). 2020
ANTIBODY RESPONSES TO THE RTS,S/AS01E VACCINE AND PLASMODIUM FALCIPARUM ANTIGENS AFTER A BOOSTER DOSE WITHIN THE PHASE 3 TRIAL IN MOZAMBIQUE
Dipòsit Digital de la UB
- Sánchez, Lina
- Vidal, Marta
- Jairoce, Chenjerai
- Aguilar, Ruth
- Ubillos, Itziar
- Cuamba, Inocencia
- Nhabomba, Augusto J.
- Williams, Nana Aba
- Díez Padrisa, Núria
- Cavanagh, David
- Angov, Evelina
- Coppel, Ross L.
- Gaur, Deepak
- Beeson, James G.
- Dutta, Sheetij
- Aide, Pedro Carlos Paulino
- Campo, Joseph J.
- Moncunill, Gemma
- Dobaño, Carlota, 1969-
The RTS,S/AS01 - " vaccine has shown consistent but partial
vaccine efficacy in a pediatric phase 3 clinical trial using a
3-dose immunization schedule. A fourth-dose 18 months after the
primary vaccination was shown to restore the waning efficacy.
However, only total IgG against the immunodominant malaria
vaccine epitope has been analyzed following the booster. To
better characterize the magnitude, nature, and longevity of the
immune response to the booster, we measured levels of total IgM,
IgG, and IgG" - " subclasses against three constructs of the
circumsporozoite protein (CSP) and the hepatitis B surface
antigen (HBsAg, also present in RTS,S) by quantitative
suspension array technology in 50 subjects in the phase 3 trial
in Manhi\xC3\xA7a, Mozambique. To explore the impact of
vaccination on naturally acquired immune responses, we measured
antibodies to " - " antigens not included in RTS,S. We found
increased IgG, IgG1, IgG3 and IgG4, but not IgG2 nor IgM, levels
against vaccine antigens 1 month after the fourth dose. Overall,
antibody responses to the booster dose were lower than the
initial peak response to primary immunization and children had
higher IgG and IgG1 levels than infants. Higher anti-Rh5 IgG and
IgG" - " levels were detected after the booster dose, suggesting
that RTS,S partial protection could increase some blood stage
antibody responses. Our work shows that the response to the
RTS,S/AS01" - " booster dose is different from the primary
vaccine immune response and highlights the dynamic changes in
subclass antibody patterns upon the vaccine booster and with
acquisition of adaptive immunity to malaria."
×
1 Versiones
1 Versiones
CORA.Repositori de Dades de Recerca
doi:10.34810/data93
Dataset. 2022
ANTIBODY RESPONSES TO THE RTS,S/AS01E VACCINE AND PLASMODIUM FALCIPARUM ANTIGENS AFTER A BOOSTER DOSE WITHIN THE PHASE 3 TRIAL IN MOZAMBIQUE
CORA.Repositori de Dades de Recerca
- Augusto J. Nhabomba
- Carlota Dobaño
- Chenjerai Jairoce
- David Cavanagh
- Deepak Gaur
- Evelina Angov
- Gemma Moncunill
- Inocencia Cuamba
- Itziar Ubillos
- James G. Beeson
- Joseph J. Campo
- Lina Sánchez
- Marta Vidal
- Nana Aba Williams
- Núria Diez-Padrisa
- Pedro Carlos Paulino Aide
- Ross L. Coppel
- Ruth Aguilar
- Sheetij Dutta
The RTS,S/AS01E vaccine has shown consistent but partial vaccine efficacy in a pediatric phase 3 26 clinical trial using a 3-dose immunization schedule. A fourth dose 18 months after the primary 27 vaccination was shown to restore the waning efficacy. However, only total IgG against the 28 immunodominant malaria vaccine epitope has been analyzed following the booster. To better 29 characterize the magnitude, nature and longevity of the immune response to the booster, we 30 measured levels of total IgM, IgG and IgG1-4 subclasses against three constructs of the 31 circumsporozoite protein (CSP) and the hepatitis B surface antigen (HBsAg, also present in RTS,S) 32 by quantitative suspension array technology in 50 subjects in the phase 3 trial in Manhiça, 33 Mozambique. To explore the impact of vaccination on naturally acquired immune responses, we 34 measured antibodies to P. falciparum antigens not included in RTS,S. We found increased IgG, 35 IgG1, IgG3 and IgG4, but not IgG2 nor IgM, levels against vaccine antigens one month after the 4th 36 dose. Overall, antibody responses to the booster dose were lower than the initial peak 37 response to primary immunization and children had higher IgG and IgG1 levels than infants. 38 Higher anti-Rh5 IgG and IgG1-4 levels were detected after the booster dose, suggesting that RTS,S 39 partial protection could increase some blood stage antibody responses. Our work shows that the 40 response to the RTS,S/AS01E booster dose is different from the primary vaccine immune 41 response and highlights the dynamic changes in subclass antibody patterns upon the vaccine 42 booster and with acquisition of adaptive immunity to malaria.
No hay resultados en la búsqueda